Fibroblast growth factor 23: are we ready to use it in clinical practice?

Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular morbidity and mortality. Over the past decade it has come clear that a disturbed calcium-phosphate metabolism, with Fibroblast Growth Factor-23 as a key hormone, is partly accountable for this enhanced risk. Nu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouma-de Krijger, Annet, Vervloet, Marc G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220896/
https://www.ncbi.nlm.nih.gov/pubmed/32130720
http://dx.doi.org/10.1007/s40620-020-00715-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220896/
https://www.ncbi.nlm.nih.gov/pubmed/32130720
http://dx.doi.org/10.1007/s40620-020-00715-2

Ejemplares similares